Marbodin (Memantine Hydrochloride)

Memantine works by blocking the NMDA‑type glutamate receptor in the brain. This non‑competitive antagonism reduces excessive calcium entry into neurons, limiting glutamate‑induced excitotoxic damage that contributes to cognitive decline in Alzheimer’s disease.

The dosage of Marbodin is individualized by the prescribing clinician based on the patient’s condition, renal function, and tolerability. Healthcare providers determine the appropriate starting dose and titration schedule according to current clinical guidelines.

Safety data for memantine hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus or infant.

To request Marbodin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Marbodin (memantine) belongs to the NMDA‑receptor antagonist class, whereas drugs such as donepezil are cholinesterase inhibitors. Memantine targets excitotoxic pathways, while cholinesterase inhibitors enhance acetylcholine signaling. Both classes may be used alone or together, offering complementary mechanisms for symptom management.

Marbodin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date printed on the label.

Marbodin is taken orally as a tablet. Patients should swallow the tablet whole with water, preferably at the same time each day. It can be taken with or without food, but consistency helps maintain stable drug levels.

The most serious adverse events include seizures, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience any signs of these conditions.

Marbodin is contraindicated in patients with known hypersensitivity to memantine or any excipients in the tablet. Caution is advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists, as the risk of adverse effects may be heightened.